Anti-amyloidogenic effect of artemin on α-synuclein

References

Ahsan, N., Mishra, S., Jain, M.K., Surolia, A., and Gupta, S. (2015). Curcumin pyrazole and its derivative (N-(3-nitrophenylpyrazole) curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of wild type and mutant α-synuclein. Sci. Rep. 5: 9862, https://doi.org/10.1038/srep09862.Search in Google Scholar PubMed PubMed Central

Anguiano, M., Nowak, R.J., and Lansbury, P.T. (2002). Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41: 11338–11343, https://doi.org/10.1021/bi020314u.Search in Google Scholar PubMed

Arispe, N. (2004). Architecture of the Alzheimer's AβP ion channel pore. J. Membr. Biol. 197: 33–48, https://doi.org/10.1007/s00232-003-0638-7.Search in Google Scholar PubMed

Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254, https://doi.org/10.1006/abio.1976.9999.Search in Google Scholar PubMed

Breydo, L., Wu, J.W., and Uversky, V.N. (2012). α-Synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta. 1822: 261–285, https://doi.org/10.1016/j.bbadis.2011.10.002.Search in Google Scholar PubMed

Chen, T., Villeneuve, T.S., Garant, K.A., Amons, R., and MacRae, T.H. (2007). Functional characterization of artemin, a ferritin homolog synthesized in Artemia embryos during encystment and diapause. FEBS J. 274: 1093–1101, https://doi.org/10.1111/j.1742-4658.2007.05659.x.Search in Google Scholar PubMed

Congdon, E.E., Necula, M., Blackstone, R.D., and Kuret, J. (2007). Potency of a tau fibrillization inhibitor is influenced by its aggregation state. Arch. Biochem. Biophys. 465: 127–135, https://doi.org/10.1016/j.abb.2007.05.004.Search in Google Scholar PubMed PubMed Central

Conte, A., Pellegrini, S., and Tagliazucchi, D. (2003). Synergistic protection of PC12 cells from β-amyloid toxicity by resveratrol and catechin. Brain Res. Bull. 62: 29–38, https://doi.org/10.1016/j.brainresbull.2003.08.001.Search in Google Scholar PubMed

Cox, D., Carver, J.A., and Ecroyd, H. (2014). Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins. Biochim. Biophys. Acta. 1842: 1830–1843, https://doi.org/10.1016/j.bbadis.2014.06.024.Search in Google Scholar PubMed

Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C.W., Merchant, K.M., Bezard, E., et al. (2015). Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 14: 855–866, https://doi.org/10.1016/S1474-4422(15)00006-X.Search in Google Scholar PubMed PubMed Central

Fink, A.L. (1998). Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold. Des. 3: R9–R23, http://doi.org/10.1016/S1359-0278(98)00002-9.10.1016/S1359-0278(98)00002-9Search in Google Scholar PubMed

Fink, A.L. (2006). The aggregation and fibrillation of α-synuclein. Acc. Chem. Res. 39: 628–634l, https://doi.org/10.1021/ar050073t.Search in Google Scholar PubMed

Friesen, E.L., De Snoo, M.L., Rajendran, L., Kalia, L.V., and Kalia, S.K. (2017). Chaperone-based therapies for disease modification in Parkinson's disease. Park. Dis. 2017: 5015307, https://doi.org/10.1155/2017/5015307.Search in Google Scholar PubMed PubMed Central

Giehm, L., Lorenzen, N., and Otzen, D.E. (2011). Assays for α-synuclein aggregation. Methods 53: 295–305, https://doi.org/10.1016/j.ymeth.2010.12.008.Search in Google Scholar PubMed

Hansen, C., Angot, E., Bergström, A.L., Steiner, J.A., Pieri, L., Paul, G., Outeiro, T.F., Melki, R., Kallunki, P., and Fog, K. (2011). α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest 121: 715–725, https://doi.org/10.1172/JCI43366.Search in Google Scholar PubMed PubMed Central

Hassani, L., and Sajedi, R.H. (2013). Effect of artemin on structural transition of β-lactoglobulin. Spectrochim Acta Part A Mol. Biomol. Spectrosc 105: 24–28, https://doi.org/10.1016/j.saa.2012.12.003.Search in Google Scholar PubMed

Honarmand, S., Dabirmanesh, B., Amanlou, M., and Khajeh, K. (2019). The interaction of several herbal extracts with α-synuclein: Fibril formation and surface plasmon resonance analysis. PLoS One 14: e0217801, https://doi.org/10.1371/journal.pone.0217801.Search in Google Scholar PubMed PubMed Central

Jellinger, K.A. (2001). Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med. 5: 1–17, https://doi.org/10.1111/j.1582-4934.2001.tb00134.x.Search in Google Scholar PubMed PubMed Central

Jellinger, K.A. (2010). Basic mechanisms of neurodegeneration: a critical update. J. Cell. Mol. Med. 14: 457–487, https://doi.org/10.1111/j.1582-4934.2010.01010.x.Search in Google Scholar PubMed PubMed Central

Khosravi, Z., Khalili, M.A.N., Moradi, S., Hassan Sajedi, R., and Zeinoddini, M. (2018). The molecular chaperone artemin efficiently blocks fibrillization of TAU protein in vitro. Cell. J. 19: 569, https://doi.org/10.22074/cellj.2018.4510.Search in Google Scholar PubMed PubMed Central

Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227: 680, https://doi.org/10.1038/227680a0.Search in Google Scholar PubMed

Maiti, P., Manna, J., Veleri, S., and Frautschy, S. (2014). Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin. Biomed. Res. Int. 2014: 14, https://doi.org/10.1155/2014/495091.Search in Google Scholar PubMed PubMed Central

Melki, R. (2018). Alpha-synuclein and the prion hypothesis in Parkinson's disease. Rev. Neurol 174: 644–652, https://doi.org/10.1016/j.neurol.2018.08.002.Search in Google Scholar PubMed

Narkiewicz, J., Giachin, G., and Legname, G. (2014). In vitro aggregation assays for the characterization of α-synuclein prion-like properties. Prion 8: 19–32, https://doi.org/10.4161/pri.28125.Search in Google Scholar PubMed PubMed Central

Porat, Y., Abramowitz, A., and Gazit, E. (2006). Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug. Des. 67: 27–37, https://doi.org/10.1111/j.1747-0285.2005.00318.x.Search in Google Scholar PubMed

Sashourpour, M., Zahri, S., Radjabian, T., Ruf, V., Pan-Montojo, F., and Morshedi, D. (2017). A study on the modulation of alpha-synuclein fibrillation by Scutellaria pinnatifida extracts and its neuroprotective properties. PLoS One. 12: e0184483, https://doi.org/10.1371/journal.pone.0184483.Search in Google Scholar PubMed PubMed Central

Selkoe, D.J. (2004). Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell. Biol. 6: 1054–1061, https://doi.org/10.1038/ncb1104-1054.Search in Google Scholar PubMed

Shahangian, S.S., Rasti, B., Hasan Sajedi, R., Khodarahmi, R., Taghdir, M., and Ranjbar, B. (2011). Artemin as an efficient molecular chaperone. Protein J. 30: 549–557, https://doi.org/10.1007/s10930-011-9359-4.Search in Google Scholar PubMed

Stefani, M. (2012). Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Prog. Neurobiol 99: 226–245, https://doi.org/10.1016/j.pneurobio.2012.03.002.Search in Google Scholar PubMed

Surmeier, D.J., Obeso, J.A., and Halliday, G.M. (2017). Parkinson's disease is not simply a prion disorder. J. Neurosci. 37: 9799–807, https://doi.org/10.1523/JNEUROSCI.1787-16.2017.Search in Google Scholar PubMed PubMed Central

Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., and Nurmi, A. (2017). Protein misfolding in neurodegenerative diseases: implications and strategies. Transl. Neurodegener 6: 6, https://doi.org/10.1186/s40035-017-0077-5.Search in Google Scholar PubMed PubMed Central

Uversky, V.N. (2002) What does it mean to be natively unfolded? Eur. J. Biochem. 269: 2–12, https://doi.org/10.1046/j.0014-2956.2001.02649.x.Search in Google Scholar PubMed

Uversky, V.N. and Fink, A.L. (2004). Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta. 1698: 131–153, https://doi.org/10.1016/j.bbapap.2003.12.008.Search in Google Scholar PubMed

Uversky, V.N., Li, J., and Fink, A.L. (2001a). Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500: 105–108, https://doi.org/10.1016/s0014-5793(01)02597-2.Search in Google Scholar PubMed

Uversky, V.N., Li, J., and Fink, A.L. (2001b). Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 276: 10737–10744, https://doi.org/10.1074/jbc.M010907200.Search in Google Scholar PubMed

Vashist, S., Cushman, M., and Shorter, J. (2010). Applying Hsp104 to protein-misfolding disorders. Biochem. Cell. Biol. 88: 1–13.10.1139/O09-121Search in Google Scholar PubMed PubMed Central

Warner, A.H., Brunet, R.T., MacRae, T.H., and Clegg, J.S. (2004). Artemin is an RNA-binding protein with high thermal stability and potential RNA chaperone activity. Arch. Biochem. Biophys. 424: 189–200, https://doi.org/10.1016/j.abb.2004.02.022.Search in Google Scholar PubMed

Xu, L. and Pu, J. (2016). Alpha-synuclein in Parkinson's disease: from pathogenetic dysfunction to potential clinical application. Park. Dis. 2016: 10, https://doi.org/10.1155/2016/1720621.Search in Google Scholar PubMed PubMed Central

Zhang, H., Xu, L.-Q., and Perrett, S. (2011). Studying the effects of chaperones on amyloid fibril formation. Methods 53: 285–294, https://doi.org/10.1016/j.ymeth.2010.11.009.Search in Google Scholar PubMed